Akebia Therapeutics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 3.82, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Akebia Therapeutics Inc in Jun 30 2026 quarter, has decreased to 96 days, compared to 98 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 420 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 1403 to 2797.

What is Receivable Turnover Ratio?
What is Akebia Therapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AKBA Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	-26.51 %	1.62 %	36.85 %	105.85 %	144.61 %
Y / Y Revenue Change	-21.36 %	-6.61 %	23.93 %	57.01 %	43.13 %
Receivable Turnover Ratio (TTM)	3.82	3.74	3.82	3.83	4.06
AKBA's Total Ranking	# 2797	# 1403	# 1360	# 1111	#
Accounts Receivable average collection period days	96	98	96	95	90
Seq. Receivable Change	-14.44 %	32.97 %	-28.98 %	-9.05 %	18.32 %
Seq. Revenue Change	-8.25 %	-7.08 %	-1.95 %	-5.93 %	8.96 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 132
Healthcare Sector	# 421
Overall Market	# 2797

Receivable Turnover Ratio Statistics
High	Average	Low
20.64	7.92	3.74
(Dec 31 2017)		(Mar 31 2026)

AKBA Company Profile • Back to AKBA Efficiency Comparisons • Compare AKBA Receivables Turnover Ratio to its Competitors

Financial Statements
Akebia Therapeutics Inc 's Accounts Receivable	$ 54 Millions	Visit AKBA's Balance sheet
Akebia Therapeutics Inc 's Sales TTM	$ 219 Millions	Visit AKBA's Income Statement
Sources of AKBA's Revenues		Visit AKBA's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
AKBA's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
AKBA's Growth Rates	AKBA's Roa	AKBA's Inventory Turnover Ratio	AKBA's Dividend Comparisons
AKBA's Profitability Ratios	AKBA's Roi	AKBA's Asset Turnover Ratio	AKBA's Dividend Growth
AKBA's Valuation Ratios	AKBA's Roe	AKBA's Financial Strength Ratios	AKBA's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Veracyte Inc	11.07	$ 544.735 Millions	$ 49.194 Millions
International Stem Cell Corporation	10.91	$ 9.514 Millions	$ 0.872 Millions
Premier Air Charter Holdings Inc	10.66	$ 31.562 Millions	$ 2.961 Millions
C4 Therapeutics Inc	10.65	$ 35.039 Millions	$ 3.290 Millions
Lifeloc Technologies Inc	10.48	$ 9.269 Millions	$ 0.884 Millions
Irhythm Holdings Inc	10.32	$ 825.702 Millions	$ 80.007 Millions
Immucell Corporation	10.29	$ 29.777 Millions	$ 2.893 Millions
Addus Homecare Corp	10.23	$ 1,475.610 Millions	$ 144.195 Millions
Dariohealth Corp	10.23	$ 21.196 Millions	$ 2.072 Millions
Radnet Inc	10.11	$ 2,268.932 Millions	$ 224.447 Millions
Utah Medical Products Inc	9.88	$ 35.679 Millions	$ 3.612 Millions
Lensar Inc	9.75	$ 60.264 Millions	$ 6.184 Millions
Biolife Solutions Inc	9.67	$ 102.718 Millions	$ 10.626 Millions
Encompass Health Corporation	9.57	$ 6,206.100 Millions	$ 648.325 Millions
The Oncology Institute Inc	9.57	$ 587.244 Millions	$ 61.364 Millions
Alumis inc	9.44	$ 7.398 Millions	$ 0.784 Millions
Enanta Pharmaceuticals Inc	9.29	$ 65.258 Millions	$ 7.027 Millions
Neuronetics Inc	9.24	$ 154.594 Millions	$ 16.732 Millions
Harmony Biosciences Holdings inc	9.22	$ 960.191 Millions	$ 104.164 Millions
Pavmed Inc	9.16	$ 0.126 Millions	$ 0.014 Millions
Ardent Health Inc	9.16	$ 6,405.940 Millions	$ 699.363 Millions
The Pennant Group Inc	9.15	$ 1,101.710 Millions	$ 120.457 Millions
Lexicon Pharmaceuticals Inc	9.14	$ 41.469 Millions	$ 4.535 Millions
Bioaffinity Technologies Inc	9.11	$ 5.901 Millions	$ 0.648 Millions
Nuvation Bio Inc	9.05	$ 169.551 Millions	$ 18.737 Millions
Sunshine Biopharma Inc	9.03	$ 35.347 Millions	$ 3.916 Millions
Biofrontera Inc	8.88	$ 45.956 Millions	$ 5.178 Millions
Novavax inc	8.86	$ 413.796 Millions	$ 46.693 Millions
Grail Inc	8.85	$ 165.263 Millions	$ 18.670 Millions
Guardant Health Inc	8.84	$ 1,183.105 Millions	$ 133.772 Millions

Date modified: 2026-09-08T18:19:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.